Medical University of Vienna
Medical University of Vienna
Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate. SCLC tumours often develop resistance to chemotherapy and thus poor prognosis is due to tumour recurrence which occurs within only five to 14 months after initial diagnosis. As a recent research study led by Balazs Döme and Karin Schelch from MedUni Vienna shows, resistant cell lines can be successfully fought with a combination of two already available therapeutic agents. The study results were published in the medical journal "Clinical Cancer Research" and offer a promising approach for the development of new therapies for this particularly aggressive type of tumour.
Autoimmune diseases are complex illnesses, the causes of which are diverse and have not yet been fully explained. A research team at MedUni Vienna has now discovered an immunoregulatory protein that could be linked to the development of autoimmune diseases such as rheumatoid arthritis. The identified component of the immune system is called "Rinl", which could provide a new target for the development of immunomodulatory therapies. The study results were recently published in the Journal of Experimental Medicine.
Marianne Graninger, assistant physician at the Center for Virology at the Medical University of Vienna, was awarded the Abbott Award 2023 of the European Society of Clinical Virology (ESCV). The annual Abbott Award is presented to an internationally aspiring scientist in the field of clinical virology.
Gerhard Prager, Head of the Bariatric Outpatient Clinic at MedUni Vienna's University Department of General Surgery, was elected as the new President of IFSO at the International World Congress of the International Federation for the Surgery of Obesity and Metabolic disorders (IFSO) in Naples. With over 3,300 participants from 150 countries, the World Congress is the most important event in the world of metabolic and bariatric surgery.
Autoimmune diseases are complex conditions whose causes are diverse and have not been fully elucidated to date. A research team at MedUni Vienna has now discovered an immunoregulatory protein that could be linked to the development of autoimmune diseases such as rheumatoid arthritis. -Rinl- is the name of the identified building block of the immune system, which may provide a new starting point for the development of immunomodulatory therapies. The study results were recently published in the Journal of Experimental Medicine.
The Youth Travel Funds Awards are presented by the Federation of European Biochemical Societies for relevant contributions to biochemical research. This enables young scientists to attend international meetings and congresses. This year's award winners include Emine Atas, PhD candidate at the Clinical Institute of Pathology at MedUni Vienna.
Leading global medical institutions, including MedUni Vienna, signed cooperation agreements with Ukrainian medical institutions at a summit in Kiev. MedUni Vienna will work with Danylo Halytsky Lviv National Medical University in addition to existing collaborations with medical universities in Odessa and Ternopil.
Patient safety is a central aspect of healthcare and plays a role wherever patient care takes place. In 2023, the International Patient Safety Day, a global WHO campaign, will focus on patient participation under the motto "Engaging patients for patient safety". University Hospital Vienna and MedUni Vienna are once again taking part this year, illuminating the main buildings in the campaign color orange. On September 18th 2023, experts will be on hand to provide information on the key areas of drug therapy safety, hand hygiene, pediatric simulation and child resuscitation.
Which examination method should be used at which point in time, and from which treatment will a specific patient benefit most? Clinical decision paths help to integrate new scientific findings into patient care as quickly as possible. A three-year project at MedUni Vienna's Department of Emergency Medicine, funded by the Austrian Research Promotion Agency (FFG), aims to make locally available, concrete medical knowledge available for digitalized treatment processes. The funding, which amounts to a seven-figure sum over three years, is provided as part of the FFG Basis Program, a program for joint projects between academic and industrial partners.